American Society of Clinical Oncology Clinical Practice Guideline Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer-Reference-Cited by-同舟云学术

American Society of Clinical Oncology Clinical Practice Guideline Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer

Published:2010-09 Issue:5 Volume:6 Page:243-246
ISSN:1554-7477
Container-title:Journal of Oncology Practice
language:en
Short-container-title:JOP

Author:

Burstein Harold J.¹,Griggs Jennifer J.¹,Prestrud Ann A.¹,Temin Sarah¹

Affiliation:

1. Dana-Farber Cancer Institute, Boston, MA; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; American Society of Clinical Oncology, Alexandria, VA

Abstract

ASCO's technology assessment of the use of aromatase inhibitors in the adjuvant setting was last updated in 2004. ASCO's Update Committee on Aromatase Inhibitors reconvened in May 2009 to update this guideline.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Health Policy,Oncology(nursing),Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JOP.000082

Reference1 articles.

1. American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer

Cited by 302 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factors Influencing Adherence to Adjuvant Endocrine Therapy After Breast Cancer Surgery;Cancer Reports;2024-08

2. Developing liver-targeted naringenin nanoparticles for breast cancer endocrine therapy by promoting estrogen metabolism;Journal of Nanobiotechnology;2024-03-19

3. Concurrent factors associated with adherence to adjuvant endocrine therapy among women with non-metastatic breast cancer;Journal of Cancer Survivorship;2024-02-24

4. Developing questions to assess and measure patients’ perceived survival benefit from adjuvant endocrine therapy in breast cancer: a mixed methods pilot study;Clinical and Experimental Medicine;2024-02-14

5. Androgen and Estrogen β Receptor Expression Enhances Efficacy of Antihormonal Treatments in Triple-Negative Breast Cancer Cell Lines;International Journal of Molecular Sciences;2024-01-25